Amgen is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $56.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Amgen's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Wezlana |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Opdivo ABP 206 |
Bristol Myers Squibb | Biosimilar | 2028 | Under FDA review | $10.1B |
| Keytruda | Merck | Biosimilar | 2028 | In clinical trials | $31.7B |
| Ocrevus ABP 692 |
Roche | Biosimilar | 2029 | Phase 3; results expected Jan 2027 | ≈$8.4B |
Company facts: SEC company tickers. Each drug page lists sources for these entries. Brand sales show the size of the market, not Amgen's share of it.